Liquid compound based on guanidinoacetic acid component

FIELD: food industry.

SUBSTANCE: this invention relates to application of at least one donor methyl group from the group of choline, methionine and betaine in a water-based drinking product immediately ready for consumption and to such a water-based drinking product immediately ready for consumption. In accordance with the invention concept, the drinking product contains a liquid food compound consisting of guanidinoacetic acid component and at least one donor methyl group from the group of choline, methionine and betaine.

EFFECT: addition of a methyl group donor selected from among choline, methionine and betaine, into the water-based drinking product immediately ready for consumption serves to increase the guanidinoacetic acid component stability.

11 cl, 2 ex

 

The present invention relates to a new food product for humans, which contains as active food ingredient guanidinosuccinic acid and donor of a methyl group from a group of choline, methionine or betaine.

First guanidinosuccinic acid was isolated .J. Weber in 1934 from the urine of dogs and people. Weber already assumed that it is the metabolic precursor of creatine (Weber, .J., Proc. Sot. Exp. Biol. and Med., 33, 172 (1934)).

A little later it was discovered that guanidinosuccinic acid is actually an endogenous substance found in animals and people, and plays a leading role in the biosynthesis of creatine. Creatine can come from food, and also be formed endogenously. The biosynthesis of creatine begins with glycine and L-arginine. In mammals, especially in the kidneys and in the liver and pancreas, guanidinium L-arginine is cleaved by the enzyme aminotransferase and N-C-N group goes to glycine. L-arginine in this case is converted to L-ornithine. Guanidinosuccinic acid formed thereby is converted to creatine in the next stage through enzyme transketolase, in vertebrates, this occurs only in the liver. In this case, the S-adenosylmethionine acts as a donor of methyl groups. Creatine then diffuses into the circulation and, thus, re is sitsa to organs-targets. Transport through the cell membrane into the cells is performed in this case via a specific carrier creatine.

Creatine plays an important role in energy metabolism in cells, where as a high-energy phosphocreatine, along with adenosine triphosphate (ATP)is an important energy reserve muscles. At rest, muscle ATP can transfer a phosphate group to creatine with the formation of phosphocreatine, which is directly dependent on ATP. During muscular work is critical as fast as possible restocking ATP. To do this in the first seconds of maximal muscular exercise has phosphocreatine. In this case, when a very fast reaction of the phosphate group is transferred to the diphosphate by the enzyme creatine kinase and, thus, to restore ATP. This is also called the reaction of Lehman.

Creatine has long been known as a food additive. During heavy muscular work, continued for a relatively long time, the reserves of natural creatine in the body is quickly depleted. For this reason, in particular, when athletic competitions aimed the introduction of creatine has had a beneficial effect on endurance and efficiency, with no known adverse processes in the body or unwanted PR is the product of decay. The reason for this is the fact that creatine, in the case of excessive intake, is excreted through the kidneys. In addition, creatine is converted at a constant speed in a circular decay product of creatinine, which is excreted through the kidneys. It is, therefore, the second way of metabolic disintegration.

In addition, it is known that taking creatine as a dietary Supplement increases the body weight. This is due to the increase in water supply to the muscles. With a long reception of creatine, however, indirectly leads, by increasing protein synthesis and/or decrease in the catabolism of protein in the myofibrils, to increase muscle mass (Int. J. Sports Med. 21 (2000), 139-145). The result is an increase in nairboi mass of the body.

Except for the creatine, it has creatine in the form of creatine monohydrate, and numerous salt of creatine, such as, for example, createaccount, citrate, pyruvate and other salts are also allowed as food additives. In the prior art at the moment, you can specify European patent EP 894083 and laid out an application Germany DE 19707694 A1 as a reference.

It was shown that the beneficial effects of creatine in humans also occur in animals, for this reason its use in various food compositions are widely disclosed. For example, in international p the patent publication WO 00/67590 describes the use of creatine or salts of creatine as supplements for breeding and feeding, as a replacement, bone meal, fish meal and/or promoters of antibiotic growth, hormones and anabolic steroids. In GB 2300103 encouraged to use creatine in the form of biscuits for dogs, in which creatine monohydrate together with meat is offered in the form of a molded mixture. Due to the poor solubility of creatine monohydrate, leading to poor bioavailability, it is recommended to use with other physiologically active compounds, preferably in salt form. Lined Germany application DE 19836450 A1 relates to the use of stable salts of pyruvic acid, and, in particular, creatine pyruvate, compositions, suitable for feeding animals.

DE 10003835 A1 relates to compositions under dehydrated conditions, usually occurring in the elderly and, in particular, people with limited mobility. In this case, creatine acts as a vehicle of water to saturate the liquid tissue, are the most vulnerable to the symptoms of dehydration.

In addition to its undisputed favourable physiological properties, creatine also, however, has a drawback: in the form of creatine monohydrate it is unstable in aqueous solutions, as it is converted to creatinine. The degree of destruction depends on the values of pH and temperature, the concentration does not play a role. Especially in acidic is th pH environment this destruction to creatinine occurs very quickly. At room temperature and the pH value of 3.5 after 3 days creatine more than 20% is converted to creatinine and its physiological effect is lost. The pH value equal to 3.5, typical, for example, soft drink. Due to the rapid destruction of creatine under these conditions, the use of creatine, including creatine monohydrate, in water or wet compositions containing water, to feed people and animals practically unacceptable. Even the pH value of the stomach, equal 1-2, may, depending on time, can lead to a significant transfer of creatine in the form of creatinine. For example, in humans it was found that after oral administration of creatine, only about 15 to 30% of creatine can be absorbed by the muscles (Greenhaff, P.L.: Factors Modifying Creatine Accumulation In Human Skeletal Muscle. In: Creatine. From Basic Science to Clinical Application. Medical Science Simposia Series Volume 14, 2000, 75-82).

Most research groups in the 1950-ies have shown in clinical studies that the introduction of guanidinoacetic acid in combination with betaine with heart disease had a positive effect in the period of the disease. Patients reported significant improvement in their General condition. In addition, it was noted improved endurance during physical tension and increasing muscle strength even after a short treatment. Patients also reported the or increased libido. 200 patients received a dose of 30 mg/kg daily for years. Side effects were noted. (H. Borsook, Borsook M.E.: The biochemical basis of betaine-glycocyamine therapy. In: Annals of western medicine and surgery 5(10), 825, 1951).

It is also known that added guanidinosuccinic acid is converted to creatine in the body. For example, in WO 91/07954 describes the introduction guanidinosuccinic acid under physiological conditions requiring increase creatine levels.

In situation of overdose methionine also know that the side effects associated with this overdose can be reduced by introducing guanidinosuccinic acid (Interrelations of choline, and methionine in growth and the action of betaine in replacing them. McKittrick, D.S. Univ. Of California, Berkeley, Archives of Biochemistry (1947), 15 133-55).

In international patent publication WO 2004/000297 described mixture for food or for pharmaceutical purposes, which is used for mammals. The mixture consists of a protein part, which contains L-serine and, as an additional component, guanidinosuccinic acid. In this case we say that the mixture is free from glycine or after hydrolysis mixture contains a ratio of L-serine to glycine greater than 2.7 to 1. As the possible forms of the product specified solutions, emulsions, suspensions, gels, bars, syrups, and, preferably, the powders.

In addition, it is known about guanidinosuccinic acid that it has antibacterial the activity and has been successfully used against bacterial infections (Staphyllococcus aureus) in experiments with animals (Preparation for protecting mammals against infection (Stanley Drug Products Inc., USA). Neth. Appl. (1976), 7 pp. NL 7411216).

In addition, guanidinosuccinic acid was also used as a food additive and food. For example, only recently it was discovered that guanidinosuccinic acid, compared to creatine that has much better bioactivity. In the experiment with Chicks even when adding less than 0.1% guanidinosuccinic acid in food have been shown to increase weight by 7% and reduced food consumption by 6% compared with the control group. In contrast, the addition of 0.2% of the creatine in food has led to an increase in weight of only 4% and reduced food consumption from 2%to 3%.

In addition, it was found that guanidinosuccinic acid exhibits its maximum activity even at the dosage at which the creatine leads to an imperceptible effect. Improvement of weight gain and improved food utilization at a very low dosage can be explained by the high conversion rate consumed guanidinosuccinic acid creatine. For example, even adding to 0.032% guanidinosuccinic acid in food chicken has led to an increase in weight by 3% and the improvement of food consumption by 3% (WO 2005/120246 A1). This is also consistent with the observation that the enzyme transketolase is in the liver in very high concentrations.

Due to the relatively poor solubility guanidinosuccinic acid in water already biladiene attempts to improve the solubility and further increase the bioavailability, and, at the same time, known positive physiological properties guanidinosuccinic acid should be preserved. For this purpose, were given new stable salts, and/or additional compounds and/or complex compounds guanidinosuccinic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, α-Ketoglutarate acid, oxalic acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, sulfuric acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid, and equally with sodium, potassium or guanidinoacetate calcium (DE 10 2005 009 990.4; hitherto unpublished).

The application of these new compounds, as compared to free guanidinosuccinic acid, can be achieved by increased solubility in water, this also applies to their stability and bioavailability of these compounds is at least equivalent to the amount of free guanidinosuccinic acid.

Given the shortcomings of the prior art in respect of creatine, the present invention was the creation of Dalada aqueous food compositions which, if possible, have a high stability in the industrial process. In addition, these compositions must be able to withstand, without breaking, high temperatures that occur during sterilization, and to be stable when stored for more than a month in the received industrial drinkable products. In addition, the connection, unlike creatine, should be resistant to the acidic environment and not be converted into creatine, breaking down in the stomach, and not be converted into creatine after exposure. Your composition should not show any physiological side effects and can be easily identified. From an economic point of view, for substances used according to the invention, manufacture them economically profitable way is also very important.

This objective is achieved by a liquid composition consisting of an aqueous solution of at least one component guanidinosuccinic acid and donor of a methyl group from a group of choline, methionine and betaine.

Unexpectedly, it was found that due to these compositions not only fully achieved the goal, but the components guanidinosuccinic acids remain stable for a relatively long time in an aqueous environment and is very quickly converted to creatine in the body. In the manufacturing process of the aqueous media is, such as environment according to the invention, also, as a rule, pastresults or sterilized. In this case, it has been unexpectedly discovered that guanidinosuccinic acid, unlike creatine, also has excellent stability at these, partly emergency conditions. These benefits were unexpected in this way in their entirety.

Preferred components guanidinosuccinic acid of the present invention are guanidinosuccinic acid and/or at least one salt, the additional compound or compound.

Especially preferred according to the invention component guanidinosuccinic acids are compounds guanidinosuccinic acid and malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, α-Ketoglutarate acid, oxalic acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, sulfuric acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoid acid and sodium, potassium or calcium.

The quantitative ratio of the components guanidinosuccinic acid and donor of methyl groups may vary within wide limits But it has been proven, that is especially favorable to use the components guanidinosuccinic acid and donor methyl group in the ratio of 1:10 to 10:1 by weight.

Particularly preferably, the liquid composition according to the invention have a water content ≥10% by weight, in particular ≥20% by mass.

It is obvious that the proposed composition according to the invention is not limited component guanidinosuccinic acid as the only active ingredient. For this reason, the present invention also relates to a variant in which the composition may contain further physiologically active compounds that are selected from the group of carbohydrates, fats, amino acids, proteins, vitamins, minerals, trace elements, as well as their derivatives and mixtures thereof.

Compared with creatine, guanidinosuccinic acid has a lower solubility in water (3.8 g per liter at room temperature). However, for the requested drug is not an obstacle, as guanidinosuccinic acid exerts its activity in a much smaller dose levels compared to creatine monohydrate. If creatine monohydrate daily dose ranges from 5 to 20 g, ordinary, then with the introduction of daily doses up to 2 g guanidinosuccinic acids are indicated significant positive effects (Borsook, H., Borsook M.E.: The biochemical basis of betaine-glycociamine therapy. In: Annals of western medicine and surgery 5(10), 82, 1951). So, for example, even in half a liter of water drink physiological significant daily dose component guanidinosuccinic acid can be introduced without problems. Possible solutions that have significantly higher concentrations of component guanidinosuccinic acid due to the recent increase in the number of suitable salts guanidinosuccinic acid.

Because of the unexpected beneficial properties of the present invention also includes, as an additional option, to obtain a preparation in the form of mineral water, lemonade, sports drink, mineral drink, fruit drink, drink fruit juice, milk drink, whey drink or alcoholic beverage or potable water.

The composition is not limited component guanidinosuccinic acid, where, in particular, the number of component guanidinosuccinic acid may be present in the product without restrictions. For economic reasons and from the point of view of power, however, the recommended amount is 0.01-4% of the mass. Particularly preferably the amount equal to 2.5 to 4.0 wt. -%, in particular 3,8% of the mass.

The present invention also relates to the use of the claimed preparation in the form of physiological tonic, in particular in the form of a functional food for people, p the pout all, for schools, sports, Wellness and/or geriatric institutions.

Obviously, it is also possible to apply the proposed remedy together with food supplements, which also includes the present invention. In this case, it would be interesting for the medical field.

In General, the proposed composition, an aqueous solution of which has a preferred limit of the pH values of 2.5-11, and using a free guanidinosuccinic acid and its salts and an additional connection in combination with a donor of a methyl group from a group of choline, methionine and betaine are preferred in the prior art. This is due to the fact that it is now possible to use these compounds not only in dry preparations, but also in the form of stable storage solutions, where the proposed compositions are also suitable for industrial preparation of drinks. Guanidinosuccinic acid and its salts and, in addition, additional compounds or complex compounds are also stable for many months in new forms, and they can, moreover, be introduced to the body with excellent bioavailability, where component guanidinosuccinic acid injected in each case, very rapidly converted in the body into creatine.

The examples below illustrate the advantages of the present invention.

Examples

1. Food add and

The following is a characteristic of the composition well oprobirovanyh compositions, ingredient which is injected at room temperature in 500 ml of fruit juice and/or water, and/or yogurt, and/or serum.

1.1 1500 mg of glucosamine

1800 mg guanidinosuccinic acid

3600 mg betaine

720 mg of magnesium L-hydrogentartrate

2000 mg glucose

500 mg of ascorbic acid

1.2 400 mg of chondroitin sulfate

4000 mg citrate guanidinosuccinic acid

8000 mg betaine

2000 mg of dicalcium phosphate

400 mg (MgSO3)4-Mg(OH)2·5H2About=about 100 mg

500 mg of vitamin C

1.3 1000 mg glucosamine

300 mg of chondroitin sulfate

2800 mg pyruvate guanidinosuccinic acid

6000 mg of betaine

500 mg methionine

3100 mg creatinephosphate

2. The storage stability

In accordance with the drawing, the storage stability of creatine was determined by comparison with a mixture of 4 parts by weight guanidinosuccinic acid and 6 parts by weight of the betaine in aqueous solution at pH 3.5 and room temperature, while creatine 3 days already more than 20% was converted into creatinine, a mixture guanidinosuccinic acid and betaine under identical conditions after 90 days in 95% of the original number was still definable guanidinosuccinic acid. Betaine under identical conditions fully stable is Yong.

1. The use of at least one donor of a methyl group from a group of choline, methionine and betaine to improve the stability of the component guanidinosuccinic acid in drinking water the product is ready to use.

2. The use according to claim 1, characterized in that the component guanidinosuccinic acid is guanidinosuccinic acid and/or at least one salt, the additional compound or compound.

3. The use according to claims 1 and 2, characterized in that the component guanidinosuccinic acid is in an amount of from 0.1 to 4.0 g/l and preferably 2.5 and 3.5 g/l

4. The use according to claims 1 to 3, characterized in that the component guanidinosuccinic acid compounds is guanidinosuccinic acid and malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, α-Ketoglutarate acid, oxalic acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, sulfuric acid, acetic acid, formic acid, 2-hydrobenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid, and also sodium, potassium or calcium.

5. The use according to claims 1 to 4, characterized in that the component guanidinosuccinic acid and donors what I methyl group are used in a ratio of from 1:10 to 10:1 by weight.

6. The use according to claims 1 to 5, characterized in that the drinking water product, ready to use, contains further physiologically active compounds from the group of carbohydrates, fats, amino acids, proteins, vitamins, minerals, trace elements, and their derivatives and mixtures thereof.

7. The use according to claims 1-6, where drinking water product, ready for use, is a mineral water, lemonade, sports drink, mineral drink, fruit drink, drink fruit juice, milk drink, whey drink or alcoholic beverage or drinking water.

8. The use according to claims 1 to 7, where drinking water product, ready for consumption, is used as a tonic physiological and, in particular, as a functional food for man, it is preferable for schools, sports, Wellness and/or geriatric institutions.

9. The use of claim 8, characterized in that the drinking water product, ready to use, use together with food supplements, in particular, in medicine.

10. The use according to claims 1 to 9, characterized in that the drinking water product, ready to use, has a pH value of 2.5-11.

11. Ready-to-use drinking the product containing liquid food composition consisting of component guanidinosuccinic acid and at least one donor metalno the group from the group of choline, methionine and betaine.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology and is intended for treatment of dystrophic diseases of cornea. Method includes introduction under posterior fornix of conjunctiva of 3-(2,2,2-trimethylhydrazium) dehydrate propionate (mildronate) water solution. Simultaneously carried out is instillation of solution into conjunctiva fornices.

EFFECT: method makes it possible to improve functional results of treatment, reduce treatment terms due to selected way and regimen of mildronate introduction in case of dystrophic processes in cornea.

2 ex

FIELD: medicine.

SUBSTANCE: claimed is application of: (a) solvating system which contains surface active substance, able to separate, remove or destruct in any other way, at least, part of biofilm, attached or adhered to a part of middle or internal ear, to the surface in nasal cavity or in sinus cavity, or to mouth or gullet tissue, and (b) polymer film-forming medical hermetic, able to form protective layer above the place, on which such biofilm was destroyed, and which possesses adhesion to natural tissues in the processed place and is resistant to separation or other destruction until natural decomposition or resorption of hermetic takes place, for manufacturing therapeutic system for treatment of infectious diseases of ear or throat, corresponding method of treatment and composition of said hermetic and anti-microbial preparation, which includes gallium-containing compound for application in the method. Demonstrated is 5.2-fold logarithmic reduction of the level of microbial contamination in vitro by cultures Staphylococcus aureus, Pseudomonas aeruginosa.

EFFECT: invention suggests efficiency of treatment by the claimed method of chronic otitis media with evaporation (COME), recurrent acute otitis media (RAOM), cholesteatoma, chronic rhinosinusitis.

71 cl, 4 dwg, 2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to therapeutic ophthalmology, and can be applied for therapy of acute thrombosis of retina veins. For this purpose per-orally prescribed is "Thrombovasim" in dose 2 pills (200 U) 2 times per day 30 minutes before meal during 20-25 days and parabulbarly sodium etamsylate (dicinone) 12.5% 0.5 ml No 5, dexamethasone 0.4% 0.5 ml with heparin 750-1000 U; intramuscularly sodium etamsylate 12.5% 2 ml 2 times per day 5-10 days, per-orally thrombo-ass 50-100 mg before going to bed for life, lasix 20 mg intramuscularly No 3 or inside diacarb 250 mg 1 time per 3 days.

EFFECT: method makes it possible to reduce risk of thrombosis in bloodstream in general without impact on indices of blood coagulation and bleeding and, respectively, minimise of risk of developing side effects and complications.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to anesthesiology and resuscitation, and can be used in states accompanied by massive blood loss. For this purpose, 5 and 3 days prior to a surgery, autoblood is sampled in amount 10 % of circulating blood volume (CBV) in each sampling to be divided on plasma and erythrocyte concentrate. For 5 preoperative days, iron preparations are administered in a therapeutic dose. Also, the surgery is preceded with analysing patient's fluid deficiency. 40 minutes prior to the surgery, 12.5 % dicynone 500 mg, one volume of autoplasma are introduced, and infusion of a rated dose of 5 % glucose and 6 % hydroxyethyl starch (HES) 500 ml is started. If the intraoperative blood loss is suggested to be 15-30 % of the CBV, additionally 6 % HES 250 ml, prednisolone in dosage 2-4 mg/kg of body weight and one volume of erythrocyte concentrate are administered. If the estimated intraoperative blood loss exceeds 30 % of the CBV, the second volumes of autoplasma and erythrocyte concentrate, another introduction of dicynone in the same dosage, 6 % HES 250 ml, prednisolone in dosage 7 - 10 mg/kg of body weight are required. Within 30 and 60 minutes after the surgery, dicynone is injected in the same dosage. 5 hours after the surgery, filter drainage fluid is returned. 6 hours after the surgery, coagulation time is determined, and if observing no hypocoagulation, Clexane is introduced in a preventive dose.

EFFECT: method allows to provide early activation of erythropoiesis combined with improved erythrocyte morphology and blood haemostatic function, considerably reduced risk of complications connected with massive transfusion of donor blood products, as well as prevented edema of interstitial spaces and development of multiple-organ-failure syndrome due to maintained effective transcapillary exchange.

5 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, pharmacology and biology, and concerns application of trecresan as a total tryptophanyl-tRNA synthetase (TRSase) activator.

EFFECT: high-active agent ensuring higher cholesterol resistance of the vascular system is developed.

2 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, pharmacology and biology, and concerns a drug stimulating muscular system development in the patients suffering protein deprivation and/or protein-energy malnutrition, containing trecresan as an active agent.

EFFECT: invention allows to extend the range of muscular tissue stimulators.

2 cl, 3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly psychoneurology, and concerns treatment of congenital structural myopathies and muscular dystrophies. That is ensure by the energotropic therapy consisting in the administration of L-carnitine in dosage 20-30 mg/kg/day, coenzyme Q10 in dosage 60-90 mg/day, succinic acid - 200 mg/day, citric acid - 50 mg/kg a day, vitamin B1 - 100 mg/kg a day, vitamin B6 - 200 mg a day, vitamin B12 - 200 mg/day for two months two times with an interval of two months.

EFFECT: such complex of drug therapy including the administration of coenzyme Q10 in high dose combined with the developed regimen provides motion activity increase in children suffering structural myopathies and congenital muscular dystrophies due to the integrated effect on various links of mitochondrial exchange.

2 ex, 7 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to pediatrics and can be used at treatment of hypotrophy in small children. That is ensured by evaluation of α1-antitrypsin and transferrin in blood serum. If the relation of α1-antitrypsin to transferrin is more than 0.58, the metabolic agents are introduced. If the relation is less than 0.58, the metabolic agents are not required.

EFFECT: method provides objectification of prescribing the metabolic agents with improving prognosis for a clinical course of said pathology and reduced time and price of treatment.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly to pharmacology and concerns application of derivatives of gamma-aminobutyric acid in the form of 4-amino-3-phenyl butane acid salts of general formula

as an anxiolytic and cerebroprotective agent reducing inclination to alcohol.

EFFECT: preparation of the agent with reduced by-effects.

2 cl, 10 tbl, 14 ex

FIELD: agriculture.

SUBSTANCE: invention relates to livestock farming. Method includes addition of betaine into mixed fodders contaminated with mycotoxins at the level of 0.18% of fodder weight.

EFFECT: method makes it possible to overcome toxic effect in animals and birds and to increase their productivity.

4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: claimed is medication for treatment of blood loss, consisting of complex representing combination of insulin 14 U, glucose solution 10% - 400 ml, sodium adenosine triphosphate 1% - 1 ml, panangin 10 ml, strophanthin acetate 0.05% - 0.25 ml, ascorbic acid 5% - 2 ml, riboxin 10ml, analgin 25% - 1 ml, polyglucinum 6% -400 ml.

EFFECT: medication in express-mode simultaneously produces rehabilitating action on all factors of blood loss etiopathogenesis, including elimination of acidosis, stress and pain syndrome.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to therapy, and deals with treatment of muscular mass loss. For this purpose, food product, which contains amino acid with branched chain (BCAA), BCAA precursor or BCAA metabolite, in combination with inhibitor of RNA-dependent proteinkynases (PKR) in efficient quantity.

EFFECT: ensuring efficient treatment of muscular mass loss in various diseases due to ability of BCAA and PKR to influence protein catabolism by various mechanisms and as a result supplement and enhance each other's ability to counteract protein catabolism.

18 cl, 10 dwg

FIELD: medicine.

SUBSTANCE: claimed is application of conjugate of heparin with lysine and ibuprofen of formula as anti-inflammatory medication with anticoagulant, antitumour and antimetastatic activity. Conjugate of heparin with lysine and ibuprofen, where R=So3H/Ac (30:70).

EFFECT: conjugate possesses anti-inflammatory activity, which is 1,4 times higher than ibuprofen activity, anticoagulant activity is comparable with pharmacopeia heparin, its antitumour activity being comparable with that of doxorubicin, cyclophosphane, vincristine, prednisolone with demonstration of antimetastatic activity.

6 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a set for hypogalactia prevention in women with thyroid diseases. The set for hypogalactia prevention in women with thyroid diseases which includes the preparations: aminophylline; no-spa; a preparation improving blood rheology specified in the group: rheopolyglucinum, fresh frozen plasma, a microdose of aspirin; an energy preparation specified in the group: glucose, actovegin; amino acid specified in the group: methionine, glutamic acid, galascorbinum; antioxidants, a ferriferous preparation specified in the group: Sorbifer Durules, tardiferon; and a vitamin complex containing vitamins A, E, C.

EFFECT: set reduces rate and severity of lactation disorders in women with a thyroid pathology and improves breast milk quality.

2 cl

FIELD: medicine.

SUBSTANCE: inhalation of the nonsteroidal anti-inflammatory drug lysine acetylsalicylate with using a nebuliser applicable in inhaling therapy for treating chronic obstructive pulmonary disease or emphysema is offered.

EFFECT: such introduction have a beneficial effect on patient's cough, as well as improves respiratory function (reduces intensity of bronchial obstruction symptoms) since the preparation is absorbed and accumulated more by the pulmonary structures involved by the disease.

4 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to an agent and a food stuff applied to stimulate gastrointestinal motor, containing glutamic acid salt with base-amino acid as an active component where base-amino acid is specified in a group consisting of arginine, lysine and ornithine, and a daily dose of the active ingredient for an adult person is 0.1 to 10 g.

EFFECT: more effective gastrointestinal motor.

12 cl, 7 ex, 8 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to anti-inflammatory composition. Method of reducing skin irritation, which includes contact of skin, displaying irritation, with preparation of personal hygiene, including composition with anti-inflammatory properties which contains (a) anti-inflammatory substance, representing extract of olive leaves (Olea Europea) and (b) anti-inflammatory agent, containing combination of sodium cocoyl amino acids, magnesium aspartate and potassium aspartate, ingredient a) and ingredient b) being represented in said composition in specified ratio (versions).

EFFECT: medications reduce skin irritation efficiently, possess synergetic anti-inflammatory effect.

12 cl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds: 2-{4-[2-(N,N-diethylamino)ethoxycarbonyl]phenyl} amino-4-oxo-4-R-phenyl-2-butenoic acids of general formula: where R=CH3O(a); where Br (b), having analgesic activity.

EFFECT: higher analgesic effect not only compared to structural anologues, but comparison standard - analgin, as well.

3 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to a new agent to reduce alcohol addiction, representing hydroxy-substituted flavonoids of general formula 1, 1 1.1 1.1 (1), where: R1, R2, R3, and R5 independently represent hydrogen atom or optionally substituted hydroxyl; R4 represents hydrogen atom, hydroxyl, optionally substituted monosaccharide, with the exception of β-D-glucopyranosyl and α-L-rhamnopyranosyl (6-deoxy- α-L-mannopyranosyl), optionally substituted disaccharide; R6 represents hydrogen atom or methyl. Preferentially, the agent represents flavonoid of general formula 1.1 where R1, R2 and R4 have the above-stated value, e.g., such as apigenin - 5,7-dihydroxy-2-(4-hydroxyphenyl)-chromene-4 of formula 1.1(1). Also the agent can represent mixed effective amount of flavonoid of general formula 1, preferentially of formula 1.1, such as apigenin of general formula 1.1(1) and thianine of formula 2 or its pharmaceutically acceptable salt.

EFFECT: improved clinical effectiveness.

9 cl, 2 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry. Vitamin E, ocimum basilicum oil, coconut oil, cloves oil, lemon oil and eucalyptus oil are mixed in the ratio, wt %: vitamin E 0.0001-0.001; ocimum basilicum oil 1.0-10.0; pine oil 1.0-20.0; coconut oil 1.0-15.0; cloves oil 1.0-10.0; lemon oil 1.0-10.0; eucalyptus oil - the rest, Cremophor is added to the prepared mixture in the ratio 1:(0.8-1.2) respectively. Then iron sulphate, alanine, tryptophan, isoleucine and water are mixed in the following ratio, wt %: iron sulphate 0.1-3.0; alanine 0.1-0.5; tryptophan 0.1-0.5; isoleucine 0.1-0.5; water - the rest. The mixed vitamin E, vegetable oils and Cremophor are combined connect in continual stirring at room temperature with the composition containing iron sulphate, alanine, tryptophan, isoleucine and water in the ratio 1:(1-500), respectively.

EFFECT: invention allows higher effectiveness of the composition.

3 cl, 13 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: carrier composition for nucleic acid delivery contains (A) a cationic lipid with a steroid skeleton and (B) a cationic lipid of quaternary ammonium salt type. The component (A) represents 3β-[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol and/or iodide 3β-[N',N',N'-trimethylaminoethane]cholesterol, the component (B) is at least one member selected from a group consisting of dimethyldioctadecylammonium bromide salt, dioleoyltrimethylammonium propane and hydrochloride N-(1-(2,3-bis(oleoyloxy)propyl)-N,N,N-trimethylammonium. The component (B) is contained in the composition in the proportion 10 to 200 weight parts in 100 weight parts of the component (A). The carrier composition is intended for nucleic acid delivery into a cell.

EFFECT: carrier composition is characterised by low toxicity, effectively delivers nucleic acids into the cells, protecting acid from degradation.

10 cl, 5 dwg, 2 tbl, 4 ex

Up!